Beta Drugs
- P/E
- 36.67
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 19.20%
- Debt to Equity
- 0.11
- EPS (TTM)
- ₹48.26
- Book Value
- ₹393.57
- Market Cap
- —
- P/E (TTM)
- 36.67
- P/B
- 4.50
- ROE
- 18.80%
- Dividend Yield
- 0.00%
- EBITDA
- ₹75.68 Cr
- 52W High
- ₹2,807.90
- 52W Low
- ₹990.10
- Day Range
- ₹1,710.40 – ₹1,790.30
- Volume
- 19,573
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Beta Drugs (this company) | ₹1,769.60 | 36.67 | ₹1,933 Cr | 4.50 | 0.00% | 18.80% | 19.20% | ₹444 Cr | ₹53 Cr |
| Median 8 companies | ₹1,771.50 | 37.74 | ₹1,25,337 Cr | 4.64 | 0.44% | 17.40% | 18.50% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 61
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 40
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 54
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 44
- Weak
- Solvency, leverage, coverage 9% weight
- Momentum
- 55
- Average
- Trend strength, vol-adjusted 12% weight
- Ownership
- 70
- Strong
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last 3 years: -7.82%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 10 | 7 | 2 |
| Oscillators | Neutral | 1 | 7 | 1 |
| Moving Averages | Strong Bearish | 9 | 0 | 1 |
Oscillators
Neutral
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 42.74
- Neutral
- MACD (12,26,9)
- −62.58
- Bullish
- SMA (50)
- 2,013.41
- Bearish
- SMA (200)
- 1,722.44
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 5Y | +27.05% |
|---|---|
| 3Y | +19.15% |
| 1Y | +6.08% |
| TTM | +15.32% |
Net profit
| 5Y | +27.86% |
|---|---|
| 3Y | +9.77% |
| 1Y | −2.38% |
| TTM | +26.19% |
Operating cash flow
| 5Y | +14.26% |
|---|---|
| 3Y | +17.17% |
| 1Y | +2.78% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | −1.76 pp |
|---|---|
| 3Y | −3.56 pp |
| 1Y | −0.93 pp |
| TTM | +0.98 pp |
Revenue by year
| Mar 2018 | ₹51.00 Cr |
|---|---|
| Mar 2019 | ₹66.00 Cr |
| Mar 2020 | ₹91.00 Cr |
| Mar 2021 | ₹116 Cr |
| Mar 2022 | ₹184 Cr |
| Mar 2023 | ₹227 Cr |
| Mar 2024 | ₹296 Cr |
| Mar 2025 | ₹362 Cr |
| Mar 2026 | ₹384 Cr |
Net profit by year
| Mar 2018 | ₹7.00 Cr |
|---|---|
| Mar 2019 | ₹8.00 Cr |
| Mar 2020 | ₹9.00 Cr |
| Mar 2021 | ₹12.00 Cr |
| Mar 2022 | ₹25.00 Cr |
| Mar 2023 | ₹31.00 Cr |
| Mar 2024 | ₹36.00 Cr |
| Mar 2025 | ₹42.00 Cr |
| Mar 2026 | ₹41.00 Cr |
Quarterly Results
₹ Cr| Particulars | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 88 | 94 | 100 | 103 | 87 | 94 | 126 | 137 |
| Expenses | 70 | 76 | 81 | 82 | 70 | 76 | 98 | 107 |
| Operating Profit | 18 | 17 | 20 | 21 | 17 | 18 | 27 | 30 |
| OPM % | 21% | 18% | 20% | 21% | 19% | 19% | 22% | 22% |
| Other Income | −1 | 2 | 3 | 3 | 2 | 3 | 2 | 2 |
| Interest | 2 | 3 | 3 | 4 | 4 | 4 | 3 | 2 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 4 | 5 |
| PBT | 12 | 12 | 16 | 16 | 10 | 12 | 22 | 26 |
| Tax % | 25% | 26% | 25% | 26% | 19% | 24% | 25% | 25% |
| Net Profit | 9 | 9 | 12 | 12 | 9 | 9 | 16 | 19 |
| EPS (₹) | 8.86 | 8.95 | 11.59 | 12.11 | 8.4 | 8.93 | 14.25 | 16.68 |
Profit & Loss
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 385 | 444 |
| Expenses | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 287 | 309 | 352 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 76 | 92 |
| OPM % | 19% | 18% | 20% | 21% | 23% | 23% | 20% | 21% | 20% | 21% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 11 | 9 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 15 | 13 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 17 | 18 |
| PBT | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 54 | 70 |
| Tax % | 1% | −2% | 21% | 27% | 28% | 25% | 25% | 26% | 24% | — |
| Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 41 | 53 |
| EPS (₹) | 7.43 | 8.84 | 9.33 | 11.6 | 24.58 | 30.42 | 36.08 | 42.02 | 40.92 | 48.26 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 |
| Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 148 | 187 | 235 | 427 |
| Borrowings | 8 | 20 | 23 | 17 | 21 | 20 | 15 | 138 | 148 | 49 |
| Other Liabilities | 9 | 22 | 28 | 31 | 45 | 55 | 82 | 101 | 103 | 170 |
| Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 | 656 |
| Fixed Assets | 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 | 125 | 220 |
| CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 9 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Other Assets | 35 | 50 | 63 | 74 | 102 | 135 | 190 | 347 | 371 | 427 |
| Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 496 | 656 |
Cash Flow
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 17 | 0 | 8 | 19 | 30 | 23 | 31 | 36 | 37 |
| Investing | −11 | −21 | −15 | −6 | −22 | −19 | −14 | −36 | −51 |
| Financing | 5 | 12 | 9 | −8 | −1 | −2 | −7 | 118 | −8 |
| Net Cash Flow | 12 | −9 | 2 | 5 | 7 | 2 | 9 | 118 | −22 |
| Free Cash Flow | 9 | −21 | −7 | 13 | 10 | 5 | 19 | −1 | −16 |
| CFO/EBITDA | 181 | 1 | 47 | 75 | 69 | 44 | 52 | 48 | 49 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 139 | 128 | 106 | 90 | 101 | 98 | 103 | 113 |
| Inventory Days | 37 | 104 | 102 | 100 | 87 | 106 | 122 | 127 | 159 |
| Days Payable | 81 | 143 | 119 | 127 | 123 | 139 | 145 | 152 | 172 |
| Cash Conversion Cycle | 60 | 100 | 111 | 79 | 53 | 68 | 75 | 79 | 100 |
| Working Capital Days | 50 | 40 | 56 | 76 | 61 | 73 | 80 | 71 | 97 |
| ROCE % | — | 18% | 21% | 22% | 36% | 34% | 33% | 27% | 19% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Beta Drugs insights
65 extracted metrics across FY18–FY27.
Documents
- Concall · Oct 2026PPT
- Q1 FY27 concall · Jul 2026PPT
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Concall · Nov 2025Transcript PPT Recording
- Concall · May 2025Transcript PPT Recording
- 22 Oct 2026
- 3 Sep 2026
- 18 Aug 2026
- 20 Jul 2026
- 25 May 2026
- 25 Sep 2026
- 20 Jan 2026
- 4 Aug 2025
- 6 May 2024
- 28 Feb 2023
- Statement of deviation(s) or variation(s) under re 22 Oct 2026
Frequently Asked Questions about Beta Drugs
What does Beta Drugs Ltd do?
Where is Beta Drugs Ltd (BETA) listed?
Which sector does Beta Drugs Ltd belong to?
What is the PE ratio of Beta Drugs Ltd?
What is the 52-week high and low of Beta Drugs Ltd?
What is the Return on Equity (ROE) of Beta Drugs Ltd?
Company Information
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BETA.md for Beta Drugs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.